Loan Originations -- $29.4 million originated, up 5% sequentially from $27.9 million in the prior quarter. Loans Held for ...

Management plans to file for regulatory approval of "Tresmi" for PAH and ILD this year, with commercial launch targeted for next year. Tyvaso DPI platform enhancement -- Introduction of 80-microgram ...

Good afternoon, everyone, and thank you for joining us. Today, I'll highlight our progress in Q3 and then provide updates on our initiatives in smartphones, smart eyewear, defense and strategic ...

GAAP basis, income from operations was USD 25.1 million, while net income attributable to TAL reached USD 42 million. Now, ...

In this quarter, we delivered a 59% improvement in diluted earnings per share, underscoring the strength of our strategy, improvements in our commercial ingredients and contract manufacturing ...